CASE REPORT NMC Case Report Journal 9 8388 2022 doi 102176jnsnmc20210125 A Case Lymphomatosis Cerebri Presenting Rapid Progression Dementia A Literature Review Shoko Merrit YAMADA1 Yusuke TOMITA1 Mikiko TAKAHASHI2 Masashi KAWAMOTO2 1Department Neurosurgery Teikyo University Hospital Mizonokuchi Kawasaki Kanagawa Japan 2Department Diagnostic Pathology Teikyo University Hospital Mizonokuchi Kawasaki Kanagawa Japan Abstract Lymphomatosis cerebri atypical form primary central nervous lymphoma PCNSL frequently causes rapid progression dementia A 68yearold woman exhibited rapidly pro gressing disorientation minimental state examination score 9 The fluidattenuated inversion recovery magnetic resonance image MRI demonstrated focal areas highsignal intensity right frontal lobe small enhancement histologically diagnosed diffuse large Bcell type lymphoma The lesion dramatically shrank enhancements identified MRI treatment highdose methotrexate MTX wholebrain radiation WBR However recov ery cognitive function poor The patient visited clinic 2 months succumbed systemic mycotic sepsis 14 months biopsy Autopsy revealed lymphomatosis cerebri pa tient based feature scattered small clusters lymphoma cells infiltrating brain paren chyma cerebral hemispheres Differentiation lymphomatosis cerebri white mat ter degenerative diseases usually challenging lymphomatosis cerebri seldom forms mass le sions In lymphomatosis cerebri lymphoma cells infiltrate regions brain tissue including basal ganglia brainstem corpus callosum addition periventricular sub cortical white matters The rapid deterioration cognitive function patient suggests rapid spread lymphomatosis cerebri necessitating early histological diagnosis prompt treatments If diagnosis obtained administration highdose MTX WBR followed rituximab cyta rabine contribute longer survival time based literature review Keywords dementia malignant lymphoma MTX lymphomatosis cerebri brain radiation Introduction Lymphomatosis cerebri considered diffusely infiltrat ing form primary central nervous lymphoma PCNSL evidence mass lesions1 Although definition established Li et al mentioned lymphomatosis cerebri diagnosed follow ing conditions met 1 T2weighted T2Wfluid attenuated inversion recovery FLAIR demonstrates abnor mal hyperintensity areas involved cerebral lobes anatomical regions brain 2 lesions ex hibit nonenhancement nonmasslike enhancement initial MRI 3 lesions pathologically firmed PCNSL2 Several cases rapidly progressive mentia lymphomatosis cerebri reported1315 In reports duration sign demen tia ranged 2 weeks 12 months The definite diag nosis tends delayed dementia symptom When patient demonstrates acute worsening disorientation strange behavior cerebrovascular diseases epilepsy toxic diseases suspected brain tumor111216 On hand cognitive function progressively declines months generative diseases suspected148913 In paper reviewed case reports lymphomatosis cerebri rapid deterioration cognitive function summa Received April 26 2021 Accepted January 31 2022 Copyright 2022 The Japan Neurosurgical Society This work licensed Creative Commons AttributionNonCommercialNoDerivatives International License 83 84 SM Yamada et al rized treatments prognosis patients includ ing case Case Report A 68yearold healthy woman taking care son suffering gastric cancer One morn ing exhibited bizarre behaviors decline cogni tive function son took emergency clinic The patients blood pressure 12070 heart rate 82 arrhythmia body temperature 363C Her minimental state examination MMSE score 9 able focus test rejected answer questions Computed tomography CT brain revealed subcortical edema right frontal lobe sug gesting stroke tumor Fig 1A The diffusionweighted image DWI MRI revealed high signals cortex right frontal lobe gadolinium dimeglumine T1weighted image GdT1W showed small enhancements Fig 1B FLAIR revealed multiple highsignal areas hemispheres arterial spin labeling ASL displayed decrease cerebral blood flow CBF right frontal Fig 1B These characteristics suggestive venous infarction encephalitis multiple sclerosis sarcoidosis malignant lymphoma Some tumor markers including sol uble interleukin2 receptor sILR2 mal range antinuclear antibodies negative Cerebrospinal fluid CSF examination revealed 1 cellÎ¼L normal glucose 71 mgdL mildly elevated pro tein 690 mgdL levels The CSF culture cytology negative Diffuse lymphoma DLBCL histologically diagnosed open biopsy enhanced lesion MRI CD20 CD10 positive MIB1 index high 50 Fig 1C Under diagnosis PCNSL courses highdose methotrexate MTX dexamethasone administration performed followed wholebrain irradiation 36 Gy24 times The series treatments completed 3 months biopsy The MMSE score recovered 13 3 months treatments patient able manage medication difficulty forming activities daily living sons help The patient visited clinic 2 months son problems Ten months treatment MMSE score decreased 11 MRI revealed progres sion brain atrophy enlarged ventricle clearer sulci Fig 2A High signals right frontal dramati cally shrank DWI FLAIR periventricular high intensities remarkably expanded No enhancement identified increase CBF symmetrically recognized ASL Fig 2A One month later patient admitted hospital comatose status high fever She died systemic mycotic sepsis origi nating urinary tract infection 14 months biopsy Autopsy performed brain large Bcell mal macroanatomically Fig 2B However histological vestigation confirmed small clusters malignant lymphoma cells scattered brain parenchyma Fig 2 C Discussion Lymphomatosis cerebi rare form PCNSL The lymphomatosis cerebri authors summarized 17 cases including case manifested dementialike symptom presented Table 1 The average age patients cases 636 years gender difference incidence Among 17 patients 6 diagnosed lymphomatosis cerebri autopsy including case No 1 6 11 13 15 17 6 di agnosed radiologically histologically ceive appropriate treatments delay diagnosis rapid worsening symptoms No 2 4 5 7 9 10 Chemotherapy withwithout radiation accurate diag nosis administered patients No 3 8 12 14 16 demonstrated better prognosis Therefore early suspicion lymphoma prompt histo logical diagnosis crucial patients lymphomato sis cerebri A rapidly progressing dementia im portant symptom patients It difficult disease distinguish lymphomatosis cerebri periventricular deep white matter hyperintensities MRI However cases lymphomatosis cerebri lesions highly contained basal ganglia thalamus brain stem corpus callosum addition periventricular subcortical white matters Table 11314 In addition lesions invade surrounding tissue concurrently lymphomatosis cerebri cause rapid deteriora tion cognitive function Early histological investigation required highsignal areas identified different regions FLAIR patients experiencing rapid decline cognitive function When DLBCL tologically diagnosed patient diagnosis lym phomatosis cerebri reliable cases lymphomatosis cerebri histologically diagnosed DLBCL136811131517 Effective treatments lymphomatosis cerebri established Even highdose MTX provide lymphomatosis cerebri patients overall survival 138 months18 shorter PCNSL pa tients19 Younger age 56 years old higher Karnofsky Per formance Status therapy MTX Bcell type dependent better prognostic factors19 As presented Ta ble 1 overall survival time short lymphoma tosis cerebri patients rapidly progressing dementia Performing WBR patients lymphomatosis cerebri accompanied dementia controversial consider ing risk dementia worsening leukoencephalopa thy high dose MTX radiation contribute good prognosis lowers risk leu NMC Case Report Journal Vol 9 2022 Rapidly Progressing Dementia PCNSL 85 Fig 1 Preoperative imaging studies pathology A Computed tomography scan admission shows focal brain edema right frontal lobe B DWI MRI demonstrates cortical subcortical small highsignal lesions small enhancedportions GdT1W iden tified white arrows corresponding highsignal lesions DWI Highsignal areas wider FLAIR identified multiple regions white dotted arrows including right frontal lobe right supplementary motor area left central semiovale periventricular areas ASL reveals low CBF right frontal lobe matching highsignal areas FLAIR MRI magnetic resonance image DWI diffusionweighted image FLAIR fluidattenuated inversion recovery GdT1W gadolini umdimegluminT1weighted image ASL arterial spin labeling C Histological investigations demonstrate cluster large lymphocytes CD20 strongly positive CD10 weakly positive fea tures The MIB1 index higher 50 NMC Case Report Journal Vol 9 2022 86 SM Yamada et al Fig 2 Followup MRI histology autopsy A MRI performed 10 months treatment completion Highsignal areas right frontal lobe dramatically shrink DWI FLAIR periventricular high intensities enlarge FLAIR obvious sulci suggesting brain atrophy There enhanced lesions GdT1W ASL shows increase CBF rightleft difference B The brain tissue autopsy displays abnormalities macroanatomically brain incised coronal section black lines The deep white matter right left frontal lobes b black squares right basal ganglia c black square focally excised histological staining C Histologically scattered small clusters lymphoma cells infiltrating brain parenchyma cere bral hemispheres right basal ganglia right frontal b left frontal c right putamen koencephalopathy especially elders PCNSL lym phoma2021 However patients undergone WBR No 8 12 14 17 survived longer Table 1 Fortunately diagnosis PCNSL highdose MTX WBR achieved case contributed survival time 14 months The survival time increased administrating high dose MTX WBR therapy ported dementia patients lymphomatosis cere bri progressively worsens poor prognosis despite treatments1522 Worsening dementia treatments suggests progression lymphomatosis cerebri necessitat NMC Case Report Journal Vol 9 2022 Rapidly Progressing Dementia PCNSL 87 Table 1 Cases lymphomatosis cerebri dementia initial symptom No Author Year Age Sex Symptoms Period Location Enhance Biopsy Tx Prognosis 5 Lewerenz J 2007 5 6 Vital A 2007 6 7 Weaver JD 2007 7 8 Kanai R 2008 8 9 Pandit L 2010 9 10 Raz E 2011 10 2011 11 12 Kitai R 2012 1 1 Bakshi R 1999 3 2 3 Rollins KE 2005 4 41 M forgetfulness disorientation F cognitive decline 75 65 M memory loss 4 80 F confusion apathy 2 M bilateral periventricular white matter pons corpus callosum 3 M periventricular white matter 6 M periventricle corpus callo sum midbrain 6 M periventricle pons periventricle thalamus hypothalamus Several months 65 F personality change forgetfulness 64 F cognitive 1 M periventricle white matter deterioration 77 M confusion disorientation 53 M personality change 1 M white matter temporal pole left insula central semiovale 2 M bilateral frontal temporal forgetfulness white matter steroid autopsy MTX CSF autopsy steroid steroid Azathioprine None None steroid WBR 36 Gy 49 M Irritability moodiness 6 M bilateral white matter No Tx parietal temporal frontal corpus callosum 72 M inattentiveness 2 M bilateral thalamus midbrain 11 Leschziner G 67 M disorientation flat affect somnolence pons dentate nuclei 10 W corpus callosum bilateral thalamus midbrain 56 F personality change 4 M lt insula thalamus rt frontal forgetfulness temporal deep white matter 13 Rivero Sanz E 60 2014 12 F personality change cognitive decline mutism 2 W bilateral frontal white matter caudate nuclei thalamus autopsy 14 Samani A 2015 13 amnesia 50 F personality change 3 W bilateral cerebral peduncle MTX autopsy steroid steroid WBR 36 Gy Chlorpromazine Phenytoin Cytarabine Rituximab WBR 40 Gy steroid 15 Lee PJ 2016 14 66 F cognitive decline 6 M lt precentral gyrus pons thalamus midbrain autopsy 16 Kerbauy MN 74 M cognitive decline 12 M lt frontal white matter MTX TMZ 2019 15 17 Our case progressive dementia 68 F strange behavior cognitive decline One day rt frontal supplemental motor area lt central semi ovale autopsy Rituximab steroid MTX WBR 36 Gy 7 months Dead 14 months Dead 1 month Dead 7 months Dead 3 months Dead 1 month Dead 11 months Alive Dead shortly 1 month Dead 19 months Bedridden 2 months Dead 10 months Alive Dead 18 months Alive 14 months Dead ing maintenance treatments Recently new effective che motherapies PCNSL reported Administra tion rituximab cytarabine effective lymphomatosis cerebri adjuvant therapy No 14 16 Table 11315 Administration combination rituxi mab methotrexate procarbazine vincristine RMPV followed reduced dose WBR23 appropriate lymphomatosis cerebri patients dementia Bruton tyrosine kinase inhibitor ibrutinib introduced novel effective agent PCNSL especially Bcell type lymphoma24 Temozolomide TMZ treatment immuno therapy selections lymphomatosis NMC Case Report Journal Vol 9 2022 cerebri adjuvant treatment following MTX ther apy152527 effect TMZ PCNSL proven When effective treatment lymphoma tosis cerebri established improvement patients cognitive function expected Acknowledgments The author expresses gratitude Edanz Group Japan editing manuscript 88 SM Yamada et al Consent Participants The consent participants obtained Conflicts Interest Disclosure There conflicts report References 1 Kitai R Hashimoto N Yamate K et al Lymphomatosis cerebri clinical characteristics neuroimaging pathological findings Brain Tumor Pathol 29 4753 2012 2 Li L Rong JH Feng J Neuroradiological features lymphomato sis cerebri systematic review English literature new case report Oncol Lett 16 14631474 2018 3 Bakshi R Mazziotta JC Mischel PS Jahan R Seligson DB Vinters HV Lymphomatosis cerebri presenting rapidly progressive dementia clinical neuroimaging pathologic findings Dement Geriatr Cogn Disord 10 152157 1999 4 Rollins KE KleinschmidtDeMasters BK Corboy JR Damek DM Filley CM Lymphomatosis cerebri cause white matter mentia Hum Pathol 36 282290 2005 5 Lewerenz J Ding X Matschke J et al Dementia leukoen cephalopathy lymphomatosis cerebri J Neurol Neurosurg Psychiatry 78 777778 2007 6 Vital A Sibon I A 64yearold woman progressive dementia leukoencephalopathy Brain Pathol 17 117118 2007 7 Weaver JD Vinters HV Koretz B Xiong Z Mischel P Kado D Lymphomatosis cerebri presenting rapidly progressive demen tia Neurologist 13 150153 2007 8 Kanai R Shibuya M Hata T et al A case lymphomatosis cerebri diagnosed early phase treated brain radiation case report literature review J Neurooncol 86 83 88 2008 9 Pandit L Chickabasaviah Y Raghothaman A Mustafa S leukoen Vasudevan A Lymhomatosis cerebria rare cause cephalopathy J Neurol Sci 293 122124 2010 10 Raz E Tinelli E Antonelli M et al MRI findings lymphomato sis cerebri description case revision literature J Neuroimaging 21 e183e186 2011 11 Leschziner G Rudge P Lucas S Andrews T Lymphomatosis cerebri presenting rapidly progressive dementia high methylmalonic acid J Neurol 258 14891493 2011 12 Rivero Sanz E Torralba Cabeza MÃ SanjuÃ¡n Portugal F GarcÃ­a Bragado F Lymphomatosis iatrogenic CreutzfeldtJakob disease BMJ Case Rep 2014 bcr2013201246 2014 cerebri mimicking 13 Samani A Davagnanam I Cockerell OC Ramsay A Patani R Chataway J Lymphomatosis cerebri treatable cause rapidly progressive dementia J Neurol Neurosurg Psychiatr 86 238240 2015 14 Lee PJ Berrios I Ionete C Smith T Lymphomatosis cerebri di agnostic challenges review literature BMJ Case Rep 2016 bcr2016216591 2016 15 Kerbauy MN Pasqualin DDC Smid J et al Diffuse large Bcell lymphoma central nervous presenting lym phomatosis cerebri dementia elderly man case report review literature Medicine 98 e14367 2019 16 Cordonnier C HÃ©non H Derambure P Pasquier F Leys D Influ ence preexisting dementia risk poststroke epileptic seizures J Neurol Neurosurg Psychiatry 76 16491653 2005 17 Sugie M Ishihara K Kato H Nakano I Kawamura M Primary central nervous lymphoma initially mimicking lym phomatosis cerebri autopsy case report Neuropathology 29 704707 2009 18 Izquierdo C Velasco R Vidal N et al Lymphomatosis cerebri rare form primary central nervous lymphoma Analysis 7 cases systematic review literature Neuro Oncol 18 707715 2016 19 Kobayashi H Yamaguchi S Motegi H et al Longterm evalu ation combination treatment single agent HDMTX chemo therapy cycles moderate dose brain irra diation primary CNS lymphoma J Chemother 31 3541 2019 20 Freilich RJ Delattre JY Monjour A DeAngelis LM Chemotherapy radiation therapy initial treatment primary CNS lymphoma older patients Neurology 46 435439 1996 21 Thiel E Korfel A Martus P et al Highdose methotrexate brain radiotherapy primary CNS lymphoma GPCNSLSG1 phase 3 randomised noninferiority trial Lancet Oncol 11 10361047 2010 22 Murakami T Yoshida K Segawa M et al A case lymphomato sis cerebri mimicking inflammatory diseases BMC Neurol 16 128 2016 23 Hattori K SakataYanagimoto M Okoshi Y et al A single insti tutional retrospective evaluation younger patients pri mary central nervous lymphomas modified RMPV regimen followed radiotherapy high dose cytarabine J Clin Exp Hematop 57 4146 2017 24 Grommes C Nayak L Tun HW Batchelor TT Introduction novel agents treatment primary CNS lymphoma Neuro Oncol 21 306313 2019 25 Faivre G Butler MJ Le I Brenner A Temozolomide single agent maintenance therapy elderly patients primary CNS lymphoma Clin Lymphoma Myeloma Leuk 19 665669 2019 26 Makino K Nakamura H Kudo M Takeshima H Kuratsu J Com plete response temozolomide treatment elderly patient recurrent primary central nervous lymphomacase report Neurol Med Chir Tokyo 47 229232 2007 27 Furuse M Nonoguchi N Omura N et al Immunotherapy nivolumab dendritic cell vaccination effective tractable recurrent primary central nervous lymphoma case report Neurol Med Chir Tokyo 57 191197 2017 Corresponding author Shoko M Yamada MD PhD Department Neurosurgery Teikyo University Hospital Mizo nokuchi 511 Futago Takatsuku Kawasaki Kanagawa 213 8507 Japan email smyamadamedteikyouacjp NMC Case Report Journal Vol 9 2022